Trial
NCT05397171
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
ImaginAb, Inc.
Condition
Urinary Bladder Neoplasms
Intervention
AZD8853
Why stopped
This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-01